SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Smruthi Organics - Quaterly Results

03 Feb 2024 Evaluate
The sales for the December 2023 quarter moved down to Rs. 234.81 millions as compared to Rs. 319.24 millions during the year-ago period.The Net Loss for the quarter ended December 2023 is Rs. -22.92 millions as compared to Net Profit of Rs. 1.88 millions of corresponding quarter ended December 2022Operating profit Margin for the quarter ended December 2023 slipped to -11.77% as compared to 16.87% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 234.81 319.24 -26.45 879.85 1042.65 -15.61 1410.41 1333.72 5.75
Other Income 0.02 0.08 -75.00 0.15 0.55 -72.73 1.07 5.83 -81.65
PBIDT -11.77 16.87 -169.77 78.86 74.85 5.36 98.87 190.12 -48.00
Interest 3.19 2.37 34.60 10.36 5.72 81.12 8.23 9.84 -16.36
PBDT -14.96 14.50 -203.17 68.50 69.13 -0.91 90.64 180.28 -49.72
Depreciation 14.52 11.63 24.85 40.67 33.34 21.99 45.72 42.56 7.42
PBT -29.48 2.87 -1127.18 27.83 35.79 -22.24 44.92 137.72 -67.38
TAX -6.56 0.99 -762.63 7.12 2.18 226.61 3.63 33.90 -89.29
Deferred Tax -0.23 -0.55 -58.18 -2.26 -8.90 -74.61 -10.97 -1.70 545.29
PAT -22.92 1.88 -1319.15 20.71 33.61 -38.38 41.29 103.82 -60.23
Equity 114.46 114.46 0.00 114.46 114.46 0.00 114.46 114.46 0.00
PBIDTM(%) -5.01 5.28 -194.86 8.96 7.18 24.85 7.01 14.25 -50.82

Smruthi Organics Share Price

117.50 -1.20 (-1.01%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×